Evidence map›Paper›PMID 31935222›Full record

ArticlePloS one2020

HIV infection does not alter interferon α/β receptor 2 expression on mucosal immune cells.

Julia Ickler, Sandra Francois, Marek Widera, Mario L Santiago, Ulf Dittmer, Kathrin Sutter

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Julia IcklerInstitute for Virology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.ORCID 0000-0003-3910-8505
Sandra FrancoisInstitute for Virology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Marek WideraInstitute for Virology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Mario L SantiagoDepartment of Medicine, University of Colorado Denver, Aurora, Colorado, United States of America.
Ulf DittmerInstitute for Virology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Kathrin SutterInstitute for Virology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
University of Colorado Denver · US

Funding

Role of Type I IFNs in Mucosal HIV-1 Immunity and PathogenesisR01AI134220 · NIAID · UNIVERSITY OF COLORADO DENVER · PI SANTIAGO, MARIO LUIS, WILSON, CARA C. · 2017 to 2021
$2.7M
NIAID NIH HHS R01 AI134220
6 · The paper itself

Abstract

The innate immune response induced by type I interferons (IFNs) plays a critical role in the establishment of HIV infection. IFNs are induced early in HIV infection and trigger an antiviral defense program by signaling through the IFNα/β receptor (IFNAR), which consists of two subunits, IFNAR1 and IFNAR2. Changes in IFNAR expression in HIV target cells, as well as other immune cells, could therefore have important consequences for initial HIV spread. It was previously reported that IFNAR2 expression is increased in peripheral blood CD4+ CXCR4+ T cells of HIV+ patients compared to HIV uninfected controls, suggesting that HIV infection may alter the IFN responsiveness of target cells. However, the earliest immune cells affected by HIV in vivo reside in the gut-associated lymphoid tissue (GALT). To date, it remains unknown if IFNAR expression is altered in GALT immune cells in the context of HIV infection and exposure to IFNs, including the 12 IFNα subtypes. Here, we analyzed the expression of surface bound and soluble IFNAR2 on Lamina propria mononuclear cells (LPMCs) isolated from the GALT of HIV- individuals and in plasma samples of HIV+ patients. IFNAR2 expression varied between different T cells, B cells and natural killer cells, but was not altered following HIV infection. Furthermore, expression of the soluble IFNAR2a isoform was not changed in HIV+ patients compared to healthy donors, nor in LPMCs after HIV-1 infection ex vivo. Even though the 12 human IFNα subtypes trigger different biological responses and vary in their affinity to both receptor subunits, stimulation of LPMCs with different recombinant IFNα subtypes did not result in any significant changes in IFNAR2 surface expression. Our data suggests that potential changes in the IFN responsiveness of mucosal immune cells during HIV infection are unlikely dictated by changes in IFNAR2 expression.

Indexed as

Antiviral AgentsHIV InfectionsHumansImmunity, InnateImmunity, MucosalInterferon Type ILymphoid TissueReceptor, Interferon alpha-betaSignal TransductionAntiviral AgentsIFNAR1 protein, humanIFNAR2 protein, humanInterferon Type IReceptor, Interferon alpha-beta

Identifiers

PMID31935222
PMCPMC6959566
OpenAlexW2999062631

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.